BioCentury | Dec 19, 2019
Finance

Truffle’s recipe for company creation

...antiviral play Abivax S.A. (Euronext: ABVX), antibiotics company Deinove S.A.. (Euronext: ALDEI) and neurology company Pharnext S.A....
BioCentury | Aug 30, 2019
Clinical News

Aug. 30 Clinical Quick Takes: Pharnext falls on FDA request for second Phase III study, plus Genentech, Novartis and Seqirus

...Pharnext shares sag on regulatory slowdown Shares of Pharnext S.A. (Euronext:ALPHA) lost €4.99 (41%) to €7.16 on...
...and sorbitol after it met the primary endpoint of its first Phase III trial, but Pharnext...
...an "unexpected intercurrent formulation event" in that study. PXT3003 is under review in China (see "Pharnext...
BioCentury | Jun 28, 2019
Company News

Management tracks: Gottlieb joins Pfizer board; plus Adaptimmune, Xencor, Arcus and more

...on Aug. 31, was previously SVP, EU medical and global medical adviser at InterMune Inc. Pharnext S.A....
...sciences group. She was chair of Mintz’s FDA practice. BioCentury Staff Adaptimmune Adaptimmune Ltd. Ambys Medicines Arcus Biosciences Inc. PDL BioPharma Inc. Pharnext S.A. Polyphor Polyphor...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...2H19; YE19 PharmaMar S.A. (Madrid:PHM) Zepsyre lurbinectedin Small cell lung cancer Phase III data 2H19 Pharnext S.A....
BioCentury | Oct 19, 2018
Clinical News

Pharnext planning U.S, EU submissions for Charcot-Marie-Tooth therapy on Phase III data

...is an oral solution of baclofen, naltrexone and sorbitol (see "Priority Review in China for Pharnext's...
...months. The high dose comprised 12 mg baclofen, 1.4 mg naltrexone and 420 mg sorbitol. Pharnext...
...of PXT3003 to treat pediatric CMT1A patients. GeneNet Co. Ltd. (Tianjing, China), a JV between Pharnext...
BioCentury | Oct 16, 2018
Clinical News

Pharnext planning U.S., EU submissions for Charcot-Marie-Tooth therapy on Phase III data

...is an oral solution of baclofen, naltrexone and sorbitol (see "Priority Review in China for Pharnext's...
...months. The high dose comprised 12 mg baclofen, 1.4 mg naltrexone and 420 mg sorbitol. Pharnext...
...of PXT3003 to treat pediatric CMT1A patients. GeneNet Co. Ltd. (Tianjing, China), a JV between Pharnext...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...NASDAQ:BMRN) Talazoparib (MDV3800) Germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer PDUFA date December Pharnext...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

.../ Specialised Therapeutics Australia Pty. Ltd. Zepsyre lurbinectedin Platinum-resistant ovarian cancer Ph III data 4Q18 Pharnext...
BioCentury | Jun 15, 2018
Clinical News

Priority Review in China for Pharnext's PXT3003

...PXT3003 to treat Charcot-Marie-Tooth 1A (CMT1A) disease. GeneNet Co. Ltd. (Tianjin, China), a JV between Pharnext...
...including Hong Kong and Macau, and Taiwan (see BioCentury, May 12, 2017) . Next half, Pharnext...
...of baclofen, naltrexone and sorbitol, and has Orphan Drug designation in the U.S. and EU. Pharnext S.A....
BioCentury | Jun 14, 2018
Company News

Priority Review in China for Pharnext's PXT3003

...to treat Charcot-Marie-Tooth 1A (CMT1A) disease. GeneNet Co. Ltd. (Tianjin, China), a joint venture between Pharnext...
...Hong Kong and Macau, and Taiwan (see BioCentury Extra, May 10, 2017) . Next half, Pharnext...
...Pharnext was down €0.04 to €7.46 on Thursday and Tasly lost RMB0.19 to RMB26.79. Sandi Wong PXT3003, PXT-3003 Pharnext...
Items per page:
1 - 10 of 39
BioCentury | Dec 19, 2019
Finance

Truffle’s recipe for company creation

...antiviral play Abivax S.A. (Euronext: ABVX), antibiotics company Deinove S.A.. (Euronext: ALDEI) and neurology company Pharnext S.A....
BioCentury | Aug 30, 2019
Clinical News

Aug. 30 Clinical Quick Takes: Pharnext falls on FDA request for second Phase III study, plus Genentech, Novartis and Seqirus

...Pharnext shares sag on regulatory slowdown Shares of Pharnext S.A. (Euronext:ALPHA) lost €4.99 (41%) to €7.16 on...
...and sorbitol after it met the primary endpoint of its first Phase III trial, but Pharnext...
...an "unexpected intercurrent formulation event" in that study. PXT3003 is under review in China (see "Pharnext...
BioCentury | Jun 28, 2019
Company News

Management tracks: Gottlieb joins Pfizer board; plus Adaptimmune, Xencor, Arcus and more

...on Aug. 31, was previously SVP, EU medical and global medical adviser at InterMune Inc. Pharnext S.A....
...sciences group. She was chair of Mintz’s FDA practice. BioCentury Staff Adaptimmune Adaptimmune Ltd. Ambys Medicines Arcus Biosciences Inc. PDL BioPharma Inc. Pharnext S.A. Polyphor Polyphor...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...2H19; YE19 PharmaMar S.A. (Madrid:PHM) Zepsyre lurbinectedin Small cell lung cancer Phase III data 2H19 Pharnext S.A....
BioCentury | Oct 19, 2018
Clinical News

Pharnext planning U.S, EU submissions for Charcot-Marie-Tooth therapy on Phase III data

...is an oral solution of baclofen, naltrexone and sorbitol (see "Priority Review in China for Pharnext's...
...months. The high dose comprised 12 mg baclofen, 1.4 mg naltrexone and 420 mg sorbitol. Pharnext...
...of PXT3003 to treat pediatric CMT1A patients. GeneNet Co. Ltd. (Tianjing, China), a JV between Pharnext...
BioCentury | Oct 16, 2018
Clinical News

Pharnext planning U.S., EU submissions for Charcot-Marie-Tooth therapy on Phase III data

...is an oral solution of baclofen, naltrexone and sorbitol (see "Priority Review in China for Pharnext's...
...months. The high dose comprised 12 mg baclofen, 1.4 mg naltrexone and 420 mg sorbitol. Pharnext...
...of PXT3003 to treat pediatric CMT1A patients. GeneNet Co. Ltd. (Tianjing, China), a JV between Pharnext...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...NASDAQ:BMRN) Talazoparib (MDV3800) Germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer PDUFA date December Pharnext...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

.../ Specialised Therapeutics Australia Pty. Ltd. Zepsyre lurbinectedin Platinum-resistant ovarian cancer Ph III data 4Q18 Pharnext...
BioCentury | Jun 15, 2018
Clinical News

Priority Review in China for Pharnext's PXT3003

...PXT3003 to treat Charcot-Marie-Tooth 1A (CMT1A) disease. GeneNet Co. Ltd. (Tianjin, China), a JV between Pharnext...
...including Hong Kong and Macau, and Taiwan (see BioCentury, May 12, 2017) . Next half, Pharnext...
...of baclofen, naltrexone and sorbitol, and has Orphan Drug designation in the U.S. and EU. Pharnext S.A....
BioCentury | Jun 14, 2018
Company News

Priority Review in China for Pharnext's PXT3003

...to treat Charcot-Marie-Tooth 1A (CMT1A) disease. GeneNet Co. Ltd. (Tianjin, China), a joint venture between Pharnext...
...Hong Kong and Macau, and Taiwan (see BioCentury Extra, May 10, 2017) . Next half, Pharnext...
...Pharnext was down €0.04 to €7.46 on Thursday and Tasly lost RMB0.19 to RMB26.79. Sandi Wong PXT3003, PXT-3003 Pharnext...
Items per page:
1 - 10 of 39